Bispecific antibody therapy

Request an Appointment
Print

Departments and specialties

Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens of specialties work together to ensure quality care and successful recovery.

Departments with related expertise

Doctors who perform this procedure

Edit search filters
close

Narrow your search

  1. Find a doctor whose last name begins with the letter A
  2. Find a doctor whose last name begins with the letter B
  3. Find a doctor whose last name begins with the letter C
  4. There are no doctors whose last name begins with the letter D
  5. There are no doctors whose last name begins with the letter E
  6. There are no doctors whose last name begins with the letter F
  7. There are no doctors whose last name begins with the letter G
  8. There are no doctors whose last name begins with the letter H
  9. There are no doctors whose last name begins with the letter I
  10. There are no doctors whose last name begins with the letter J
  11. Find a doctor whose last name begins with the letter K
  12. There are no doctors whose last name begins with the letter L
  13. There are no doctors whose last name begins with the letter M
  14. There are no doctors whose last name begins with the letter N
  15. There are no doctors whose last name begins with the letter O
  16. There are no doctors whose last name begins with the letter P
  17. There are no doctors whose last name begins with the letter Q
  18. There are no doctors whose last name begins with the letter R
  19. Find a doctor whose last name begins with the letter S
  20. There are no doctors whose last name begins with the letter T
  21. There are no doctors whose last name begins with the letter U
  22. Find a doctor whose last name begins with the letter V
  23. There are no doctors whose last name begins with the letter W
  24. There are no doctors whose last name begins with the letter X
  25. There are no doctors whose last name begins with the letter Y
  26. Find a doctor whose last name begins with the letter Z
Reset all filters

Displaying 1-8 out of 8 doctors available

  1. Stephen M. Ansell, M.D., Ph.D.

    Stephen M. Ansell, M.D., Ph.D.

    1. Internist
    2. Oncologist
    3. Hematologist
    1. Rochester, MN
    Areas of focus:

    CAR-T cell therapy, Bispecific antibody therapy, B-cell lymphoma, Non-Hodgkin lymphoma, Burkitt lymphoma, Follicular ly...mphoma, Hodgkin lymphoma

  2. Tanios S. Bekaii-Saab, M.D.

    Tanios S. Bekaii-Saab, M.D.

    1. Oncologist
    1. Phoenix, AZ
    Areas of focus:

    Chemotherapy for colon cancer, Bispecific antibody therapy, Cholangiocarcinoma, Colon cancer, Pancreatic cancer, Liver ...cancer, Esophageal cancer, Anal cancer, Stomach cancer, Rectal cancer, Gallbladder cancer, Carcinoma of unknown primary, Neuroendocrine tumor, Gastrointestinal stromal tumor, Small bowel cancer

  3. Joselle M. Cook, M.B.B.S.

    Joselle M. Cook, M.B.B.S.

    1. Internist
    2. Oncologist
    3. Hematologist
    1. Rochester, MN
    Areas of focus:

    Bispecific antibody therapy, Multiple myeloma

  4. Prashant Kapoor, M.D.

    Prashant Kapoor, M.D.

    1. Oncologist
    2. Hematologist
    1. Rochester, MN
    Areas of focus:

    Bone marrow transplant, CAR-T cell therapy, Bispecific antibody therapy, Multiple myeloma, Amyloidosis, Waldenstrom mac...roglobulinemia

  5. Shaji Kumar, M.D.

    Shaji Kumar, M.D.

    1. Internist
    2. Hematologist
    1. Rochester, MN
    Areas of focus:

    Bone marrow transplant, CAR-T cell therapy, Bispecific antibody therapy, Multiple myeloma, Amyloidosis

  6. Jason S. Starr, D.O.

    Jason S. Starr, D.O.

    1. Hematologist / Oncologist
    1. Jacksonville, FL
    Areas of focus:

    Chemotherapy for colon cancer, Bispecific antibody therapy, Colon cancer, Pancreatic cancer, Liver cancer, Esophageal c...ancer, Stomach cancer, Pancreatic neuroendocrine tumor, Neuroendocrine tumor

  7. J.C. C. Villasboas Bisneto, M.D.

    J.C. C. Villasboas Bisneto, M.D.

    1. Internist
    2. Oncologist
    3. Hematologist
    1. Rochester, MN
    Areas of focus:

    Bone marrow transplant, CAR-T cell therapy, Bispecific antibody therapy, B-cell lymphoma, Lymphoma, Follicular lymphoma

  8. Mojun Zhu, M.D.

    Mojun Zhu, M.D.

    1. Oncologist
    1. Phoenix, AZ
    Areas of focus:

    Bispecific antibody therapy, Cholangiocarcinoma, Colon cancer, Pancreatic cancer, Hepatocellular carcinoma, Esophageal ...cancer, Anal cancer, Stomach cancer, Rectal cancer, Neuroendocrine tumor, Small bowel cancer

Research

Mayo Clinic doctors and scientists in the David F. and Margaret T. Grohne Cancer Immunology and Immunotherapeutics Research Program are pursuing cutting-edge research to better understand the interaction between the immune system and cancer cells.

Mayo Clinic doctors are actively conducting clinical trials to develop new ways of using bispecific antibodies to treat cancers. This includes combining bispecific antibodies with other powerful therapies and replacing traditional therapies with newer bispecific antibody-based therapies.

Cancer research is conducted in coordination with Mayo Clinic Comprehensive Cancer Center. Mayo Clinic Comprehensive Cancer Center receives funding from the National Cancer Institute and is designated as a comprehensive cancer center. This designation recognizes the institution's scientific excellence and multidisciplinary resources focused on cancer prevention, diagnosis and treatment.

Publications

See a list of publications about bispecific antibody therapy by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine.

Research Profiles

Edit search filters
close

Narrow your search

View all physicians • All Locations

By Mayo Clinic Staff

Bispecific antibody therapy care at Mayo Clinic

Request an appointment
AboutCare at Mayo Clinic
Jan. 24, 2026
Print
  1. Klein C, et al. The present and future of bispecific antibodies for cancer therapy. Nature Reviews Drug Discovery. 2024; doi:10.1038/s41573-024-00896-6.
  2. Manis JP. Overview of therapeutic monoclonal antibodies. https://www.uptodate.com/contents/search. Accessed Sept. 30, 2025.
  3. Guidi L, et al. Bispecific antibodies in hematologic and solid tumors: Current landscape and therapeutic advances. American Society of Clinical Oncology Educational Book. 2025; doi:10.1200/EDBK-25-473148.
  4. Gu Y, et al. Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors. Molecular Diagnosis & Therapy. 2024; doi:10.1007/s40291-024-00734-w.
  5. Verma V, et al. Bispecific antibodies in clinical practice: Understanding recent advances and current place in cancer treatment landscape. Clinical and Experimental Medicine. 2025; doi:10.1007/s10238-024-01520-y.
  6. Jain MD, et al. Easy as ABC: Managing toxicities of antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies. ASCO Educational Book. 2025; doi:10.1200/EDBK-25-473916.
  7. Tan CR, et al. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group study. Blood Cancer Journal. 2025; doi:10.1038/s41408-025-01259-z.
  8. Choi SM, et al. Mechanism of action and pharmacokinetics of approved bispecific antibodies. Biomolecules & Therapeutics. 2024; doi:10.4062/biomolther.2024.146.
  9. Medical review (expert opinion). Mayo Clinic. Sept. 30, 2025.
  10. Tecvayli (prescribing information). Janssen Biotech; 2022 https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf. Accessed Sept. 29, 2025.
  11. Imdelltra (prescribing information). Amgen; 2024. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Imdelltra/imdelltra_fpi.pdf. Accessed Oct. 1, 2025.
  12. Raje N, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel. Blood Cancer Journal. 2023; doi:10.1038/s41408-023-00879-7.
  13. Britto J, et al. Bispecific antibody toxicities. CMAJ. 2025; doi:10.1503/cmaj.241384.
  14. Morris EC, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology. 2022; doi:10.1038/s41577-021-00547-6.
  15. Derman B, et al. Real-world evidence evaluating teclistamab in patients with relapsed/refractory multiple myeloma: A systematic literature review. Cancers. 2025; doi:10.3390/cancers17071235.
  16. Health Education & Content Services. Staying connected with remote patient monitoring. Mayo Clinic; 2022.
  17. Altered immunocompetence. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html. Accessed Nov. 14, 2025.
  18. Rybrevant (prescribing information). Janssen Biotech; 2021. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  19. Blincyto (prescribing information). Amgen; 2014. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  20. Elrexfio (prescribing information). Pfizer; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  21. Hemlibra (prescribing information). Genentech; 2017. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  22. Epkinly (prescribing information). Genmab US; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  23. Vabysmo (prescribing information). Genentech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  24. Lunsumio (prescribing information). Genentech; 2022. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  25. Kimmtrak (prescribing information). Immunocore; 2022. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  26. Haydu E, et al. The rules of T-cell engagement: Current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Advances. 2024; doi.org/10.1182/bloodadvances.2021004535.
  27. Columvi (prescribing information). Genentech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 20, 2025.
  28. Talvey (prescribing information). Janssen Biotech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 26, 2025.

Related

Bispecific antibody therapy